Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357389 · ClinicalTrials.gov registry record · NA
Virtual Reality for ICU Delirium Prevention
A NA study of ICU Delirium, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 822
- Enrollment target
- 1
- Study location
NCT07357389: Recruiting NA study of ICU Delirium, sponsored by Cedars-Sinai Medical Center.
NCT07357389 is a NA study of ICU Delirium that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 822 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07357389, a NA study of ICU Delirium, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 822 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether daily exposure to immersive virtual reality (VR) can reduce the incidence of delirium in high-risk, non-intubated ICU patients. Participants will be randomized to either standard ICU care or standard care plus once-daily 15-minute VR sessions consisting of calming natural scenes, guided meditation, and music. The study population includes adult surgical ICU patients at Cedars-Sinai who are CAM-ICU negative at enrollment and possess at least one established risk factor for delirium. Outcomes will include the incidence and duration of delirium, ICU and hospital length of stay, feasibility of the VR intervention, and the frequency of adverse events. By targeting a high-risk population with an innovative non-pharmacologic therapy, this trial aims to generate data to support integration of VR into ICU delirium prevention protocols.
Primary Outcome
Using the CAM-ICU assessment, patients will be evaluated for the development of ICU delirium
Conditions Studied
Interventions
- DEVICE Virtual Reality therapeutics
Study Locations (1)
California
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2026-03-10 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT07357389 shows while recruiting
NCT07357389 is an interventional study that assigns participants to a tested intervention. The registered 822 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (41% lower).
The record links to 1 condition, with ICU Delirium appearing as the primary indexed condition, and to 1 intervention - of which Virtual Reality therapeutics is the first listed.
NCT07357389 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07357389 about?
NCT07357389 is a clinical study titled "Virtual Reality for ICU Delirium Prevention". The purpose of this study is to evaluate whether daily exposure to immersive virtual reality (VR) can reduce the incidence of delirium in high-risk, non-intubated ICU patients. Participants will be randomized to either standard ICU care or standard care plus once-daily 15-minute VR sessions consisti...
What is the current status of trial NCT07357389?
This trial is currently recruiting. It is a NA study. The enrollment target is 822 participants. The study started on 2026-03-10. Estimated completion is 2028-04.
What conditions does trial NCT07357389 study?
This clinical trial studies the following conditions: ICU Delirium.
What interventions are being tested in trial NCT07357389?
The interventions under investigation include: Virtual Reality therapeutics (DEVICE).
Who is sponsoring clinical trial NCT07357389?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07357389 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ICU Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07357389's enrollment target sits among peer trials
822 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
- NCT06091254 · 822 participants · Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- NCT06944509 · 824 participants · NA
RADIQAL Study (Radiation Dose and Image Quality Trial)
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI